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Abstract
Differentiated thyroid cancer (DTC) represents the most common form of thyroid 
neoplasms and is becoming increasingly prevalent. Evidence suggests a possible 
relationship between DTC diagnosis and subsequent atrial fibrillation (AF). If confirmed, 
this may present an alarming health risk (AF) in an otherwise condition with a relatively 
good prognosis (DTC). The aim of this systematic review and meta-analysis is to provide 
for the first time a pooled estimate of AF incidence in DTC patients in comparison to 
healthy controls. A detailed search in electronic databases, clinical trial registries and grey 
literature was performed to identify studies reporting the incidence of AF in DTC patients. 
Newcastle–Ottawa quality assessment scale was used to assess study quality. We used 
a random effects (RE) generalized linear mixed model (GLMM) in pooling of individual 
studies and also calculated a prediction interval for the estimate of a new study. Six 
observational studies met the eligibility criteria, which included totally 187,754 patients 
with DTC and 199,770 healthy controls. The median follow-up period was 4.3 to 18.8 
years; the incidence rate of AF was 4.86 (95% CI, 3.29 to 7.17, I2 = 96%) cases per 1000 
person-years, while the incidence rate ratio was 1.54 (95% CI, 1.44 to 1.65, I2 = 0%, 95% PI, 
1.33 to 1.78).This is the first meta-analysis to confirm that patients with DTC are at a high 
risk for developing AF, which may be attributed to a state of iatrogenic hyperthyroidism 
due to long-term thyrotropin suppression therapy.
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Differentiated thyroid cancer (DTC), which includes 
papillary (85%) and follicular (12%) cancer, represents 
the most common form of malignant thyroid neoplasms. 
The age distribution is binomial (first peak at 35–40 years 
old, second peak over 70 years) with a consistent female 
preponderance (Rahbari et al. 2010, DeSantis et al. 2014). 
DTC is becoming increasingly prevalent, which is largely 
attributable to the increased detection of small papillary 
thyroid carcinomas and might be related to the widespread 
use of neck ultrasonography and/or cytological analysis 
of fine-needle aspirations (Davies & Welch 2014, Li et al. 
2020). Thus, a timely diagnosis of the disease is common, 
so that an appropriate therapy is often instituted early, 
leading to a decrease in the disease-specific mortality rates 
since 1970s (https://www.cancerresearchuk.org/health-
professional/cancer-statistics/statistics-by-cancer-type/
thyroid-cancer/mortality; accessed (September) (2020)). 
In all, DTC has a favourable prognosis and, therefore, 
long-term survival is expected (DeSantis  et  al. 2014, 
Viola et al. 2016).
Total thyroidectomy is the cornerstone of initial 
management with or without adjuvant radioiodine-131 
ablation (RAI). According to the European and American 
Thyroid Association, long-term levothyroxine suppression 
of thyrotropin (THST) is recommended in high- and 
selected intermediate-risk patients, whereas a low-normal 
thyroid-stimulating hormone (TSH) is considered to 
be the optimal therapeutic target for low-risk patients 
(Perros  et  al. 2014, Haugen  et  al. 2016). The rationale 
behind this approach is the minimization of potential 
TSH-mediated stimulation of tumour growth and the 
prevention of recurrence (Jonklaas  et  al. 2006, Brabant 
2008, Goemann et al. 2017). 
Over aggressive thyroxine (T4) therapy may lead 
to iatrogenic thyrotoxicosis, thus increasing the risk of 
atrial fibrillation (AF), mostly by increasing the heart rate 
(positive chronotropic effect) and conduction velocity 
(positive dromotropic effect). Impaired ventricular 
relaxation, the elevation of left atrial pressure due to 
increased left ventricular mass, ischaemia resulting from 
increased resting heart rate and re-entry might also be 
implicated in the development of AF (Shargorodsky et al. 
2006, Bielecka-Dabrowa et al. 2009, Biondi & Cooper 2010, 
Abdulrahman  et  al. 2011). In patients with endogenous 
hyperthyroidism (e.g. Graves’ disease), low TSH levels are 
strongly related to AF risk (Camm et al. 2010). Therefore, it 
is reasonable to speculate that a similar relationship might 
exist in exogenous hyperthyroidism due to aggressive 
THST. On the other hand, endogenous and iatrogenic 
thyrotoxicosis should not be considered as identical 
clinical states in terms of circulating thyroid hormones 
since free triiodothyronine (T3) levels (the ligand to 
nuclear thyroid receptors in the cell) differ between the 
two states. Different T3/T4 ratios might also be associated 
with different health outcomes (Biondi & Cooper 2008).
In any case, if a high AF risk is confirmed in patients 
treated for DTC, then this might also increase the risk of 
stroke, heart failure and overall cardiovascular morbidity/
mortality, and could be of major concern, considering 
the favourable long-term prognosis of DTC (Biondi & 
Cooper 2010, DeSantis  et  al. 2014, Carhill  et  al. 2015). 
Furthermore, RAI and in specific total cumulative dose 
might also be associated with the incidence of AF (Klein 
Hesselink  et al. 2015). In other words, two independent 
predisposing factors to AF risk might be present in the 
management of DTC patients, while little is known about 
the magnitude of the effect (if any) and/or the individual 
patients’ characteristics that might affect this risk. 
To this end, we performed a systematic review and 
meta-analysis to assess for the first time the incidence of 
AF in DTC patients and collate it in reference to healthy 
controls.
Methods
The present systematic review followed the Preferred 
Reporting Items for Systematic reviews and Meta-Analyses 
(PRISMA) statement (Liberati  et  al. 2009). All research 
was conducted according to a protocol registered in OSF 
(Open Science Framework), available at: https://doi.
org/10.17605/OSF.IO/YPCW7.
Literature search strategy and study selection
The bibliographic search (detailed in Table 1) was 
performed in the electronic databases Medline (via the 
PubMed platform), the Cochrane Central Register of 
Controlled Trials (CENTRAL) and clinicaltrials.gov. A 
basic search strategy was developed for PubMed and 
modified accordingly for other research engines. We also 
searched PROSPERO to check if any similar meta-analysis 
is in progress in order to avoid duplication with our study. 
Conference abstracts and references of relevant studies 
and systematic reviews were perused and experts were 
contacted in order to identify unpublished studies.
Records retrieved from the search were imported 
in reference management software. After removing the 
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duplicate records, two reviewers (GK and ID) screened 
titles and abstracts independently and full texts were 
investigated for eligible studies. Differences in opinion 
between the two reviewers were resolved by a third 
reviewer (CA). 
Eligibility and exclusion criteria
We included original case-control and cohort studies 
reporting estimates of the risk of incident AF in patients 
with DTC. There was no limitation in publication date 
or language. Pre-defined exclusion criteria were applied 
to the following studies: (i) with no original data (review 
articles, commentaries, editorials) or of case-series design, 
(ii) not reporting on incident AF rates, (iii) with less than 
20 individuals, (iv) with unknown or less than 1-year 
duration of follow-up, (v) with no accessible or extractable 
data. A detailed summary of the excluded studies is 
presented in the flow chart (Fig. 1). 
Data extraction and quality assessment in 
individual studies
Two reviewers (G K, I D) examined the search results 
and screened the titles and abstracts. Subsequently, full 
texts of the selected studies were obtained and evaluated 
independently by the two reviewers (G K, I D) for 
Table 1 MEDLINE search strategy.*
Search terms Results
1. Arrhythmia (All Fields) 240,499
2. Atrial fibrillation (All Fields) 77,853
3. 1 OR 2 259,607
4. Thyroid cancer (All Fields) 75,780
5. Thyroid neoplasm (All Fields) 67,461
6. Thyroid carcinoma (All Fields) 71,642
7. 4 OR 5 OR 6 78,956
8. Exp animals/not humans.sh. 263,760
9. 3 AND 7 NOT 8 187
10. Atrial fibrillation (Mesh) 55,914
11. Thyroid neoplasms (Mesh) 52,823
12. 10 AND 11 25
*Via Pubmed, performed on 5 December 2019.
Figure 1
Summary of evidence search and selection.
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eligibility. Any discordance regarding study eligibility was 
resolved by consultation with a senior author (K T). When 
necessary, we attempted to contact the study authors to 
clarify uncertainties in the study design or results. 
Two reviewers (G K, I D) assessed the potential 
risk of bias in the included studies using the version of 
the Newcastle–Ottawa quality assessment scale (NOS) 
developed for case-control studies. On the basis of NOS 
quality assessment scale, a maximum of nine points was 
assigned for the least risk of bias in three domains: (i) 
selection of study groups (four points); (ii) comparability 
of groups (two points); (iii) ascertainment of exposure 
(three points) for case-control studies (http://www.
ohri.ca/programs/clinical_epidemiology/oxford.asp). 
Any disagreement was resolved by discussion or by the 
involvement of a senior investigator (K T). 
Data synthesis and statistics
The primary outcome was the aggregate incidence rate (IR) 
of AF in patients with DTC. Following Stijnen et al., we 
used a random effects (RE) generalized linear mixed model 
(GLMM) in pooling of individual studies (Stijnen  et  al. 
2010, Schwarzer & Chemaitelly 2019). Data referring 
to matched, cancer-free, control patients were also 
considered for quantitative synthesis. A pooled incidence 
rate ratio (IRR) estimate was calculated using a random 
effects GLMM model, as well. A prediction interval (PI) for 
the estimate of a new study was also calculated as proposed 
by Higgins (Higgins  et  al. 2009).The total number of 
person-years at risk, as reported by individual studies, was 
used. When these were not reported, the average length of 
follow-up and the total number of patients at the end of 
the study were used to approximate the total person-years 
(Pedder et al. 2016). In addition, to investigate sources of 
potential heterogeneity and to test the robustness of our 
results, a sensitivity analysis, incorporating studies with 
the highest quality, was conducted. A score of 9 points 
in the NOS quality assessment scale indicated a highest 
quality study. Analysis was performed in R v3.6.0 utilizing 
the meta package (Schwarzer 2007)
Results
Search results and characteristics of the 
eligible studies
The systematic literature search identified 281 potentially 
eligible articles; 6 studies finally met the eligibility criteria 
and were included in the review (Fig. 1). All included 
studies were observational in design and were conducted 
in Canada, the Netherlands, Finland, Korea, the United 
States and the United Kingdom between 2012 and 2019. 
Studies and patient characteristics are summarized in 
Table 2. Briefly, a total of 387,524 people were included 
in the studies of the meta-analysis: 187,754 patients with 
DTC and 199,770 healthy, cancer-free, matched controls 
with a follow-up time (mean or median) ranging from 4.3 
to 19 years. The NOS scores of the studies were above 5 
and presented in Table 3. 
Systematic review
Four studies reported that the risk of incident AF was 
significantly higher in DTC patients compared to cancer-
free controls, adjusted for established risk factors, such 
as age, hypertension, diabetes and coronary artery 
disease (Klein Hesselink et al. 2015, Pajamäki et al. 2018, 
Suh et al. 2019, Toulis et al. 2019), whereas another study 
reported a higher AF prevalence when compared to the 
general population (Abonowara  et  al. 2012). The sixth 
study included a cohort of DTC patients with low- and 
intermediate-risk for recurrence, examining the benefits of 
TSH suppression and potential skeletal and cardiovascular 
adverse events (Wang et al. 2015). In this study, the rate 
of AF was also reported. Overall, the IR for AF in DTC 
patients ranged from 2.2 to 9.36 per 1000 person-years; 
in those studies which included healthy controls, the 
adjusted hazard ratio (aHR) for AF in the DTC cohort 
ranged from 1.29 to 2.5.
None of the included studies could provide evidence 
for a possible association between the aggressiveness of 
THST and the risk for AF, although indirect evidence 
was reported. Suh  et al. reported that DTC patients were 
consistently found to be at a higher risk of developing AF 
across all categories of levothyroxine dosage, but the aHR 
was found to be highest in the highest dosage quartile, 
which might be indicative of a dose-response relationship 
(Suh et al. 2019). Of note, no correction for body weight 
was available. Finally, Pajamaki et  al. reported that 
patients with TSH <0.1 mU/L had an increased risk (HR: 
1.27, CI:1.03–1.58) of cardiovascular morbidity mostly 
attributed to AF (Pajamäki et al. 2018). 
The relation between RAI and incident AF was explored 
in a single study. Klein et  al. reported that cumulative 
radioiodine dose might be correlated with a higher AF risk 
independently of TSH levels (Klein Hesselink et al. 2015). 
A subgroup analysis focusing on the patients treated 
with adjuvant RAI was also planned, but not conducted, 
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because data regarding incident AF in this cohort were not 
available.
In patients with DTC, the risk of AF was related 
significantly with older age and hypertension in two 
studies (Abonowara et al. 2012, Klein Hesselink et al. 2015). 
On the contrary, a large retrospective cohort study with 
6900 Swedish DTC patients reported that DTC patients 
were at a higher risk of hospitalization for AF, especially 
those who were younger men and during the first 5 years 
of the follow-up time (Zoltek et al. 2020). This study was 
not included in our systematic review and meta-analysis 
as the primary outcome was the risk of hospitalization for 
AF and other cardiovascular endpoints. Only two studies 
involved patients without pre-existing circulatory disease, 
while one study was limited to low- and intermediate-risk 
patients (Wang  et  al. 2015, Suh  et  al. 2019, Toulis  et  al. 
2019). Table 4 presents the event rate (AF) in patients with 
DTC and in healthy controls.
Meta-analysis 
The overall IR of AF was estimated to be 4.86 (95% CI, 
3.29 to 7.17, I2 = 96%, RE) cases per 1000 person-years 
(Fig. 2). Additionally, the pooled IRR of AF was equal to 
1.54 (95%CI, 1.44 to 1.65, I2 = 0%, 95%PI, 1.33 to 1.78, 
RE) (Fig. 3). To further explore and address the issue of 
high heterogeneity among studies in our meta-analysis 
(I2 = 96%), a sensitivity analysis was undertaken including 
the highest quality observational studies (NOS = 9) (Klein 
Hesselink  et  al. 2015, Pajamäki  et  al. 2018, Toulis  et  al. 
2019). In this analysis, incident AF was found to be 
6.13 cases per 1000 person-years (95% CI, 5.19 to 7.23, 
I2 = 40%, RE), while the IRR of AF was 1.49 (95%CI, 1.17 
to 1.89, I2 =34%, RE) .
Discussion
In this study, the incidence of AF in patients with DTC 
by meta-analysis was found to be 4.86 cases per 1000 
person-years. This estimate was based on studies with an 
adequate follow-up duration (mean follow-up ≥ 4.3 years), 
considering that aggressive suppression therapy, when 
needed, is usually applied in the first 5 years after DTC 
diagnosis. To further quantify the magnitude of difference 
between patients with DTC and their healthy counterparts, 
we provided an IRR approximation, incorporating in 
parallel variations in the length of follow-up among 
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expected to be at a higher risk for AF, namely about 50%, 
compared to healthy controls (IRR =1.54). 
In line with the European (Perros  et  al. 2014) and 
American guidelines (Haugen  et  al. 2016), long-term 
levothyroxine suppression following total thyroidectomy 
with or without adjuvant RAI is the recommended 
approach in patients with high-risk DTC. This intervention, 
aimed to prevent tumor recurrence, especially in the high 
and intermediate-risk group, leads to a state of iatrogenic 
hyperthyroidism. Endogenous hyperthyroidism is a 
well-known risk factor for AF, ischaemic stroke, angina, 
myocardial infarction and congestive heart failure 
in patients with underlying cardiovascular disease 
(Sawin et al. 1994, Ertek & Cicero 2013). Similarly, overt 
and subclinical exogenous hyperthyroidism may also 
be associated with cardiovascular disease, including AF, 
diastolic dysfunction, and left ventricular hypertrophy 
(Shargorodsky  et  al. 2006, Biondi & Cooper 2010, 
Abdulrahman et al. 2011). 
In a meta-analysis of 8711 participants from 5 cohorts 
with a mean follow-up of 8.8 years, the estimated incidence 
of AF in patients with subclinical hyperthyroidism was 
17.1 cases per 1000 person-years (Collet  et  al. 2012). 
Furthermore, Selmer  et  al. (2012) reported that incident 
AF in patients with overt and subclinical endogenous 
hyperthyroidism was 12.5 cases and 8.4 cases per 1000 
person-years, respectively, based on a study population 
of 586,460 individuals. Finally, another large population-
based study from Norway (932,913 people) calculated 
that incident AF was ~35.0 cases per 1000 person-years 
within 3 months after the diagnosis of endogenous 
hyperthyroidism, declining to ~9.3 within 3 years of 
follow-up (Dekkers et al. 2017). The above findings suggest 
that the risk of AF is consistently elevated across different 
types of hyperthyroidism.
Patients with endogenous thyroid disease and a 
suppressed TSH are at a higher risk for AF. It is reasonable 
to anticipate a similar relationship in states of exogenous 
hyperthyroidism due to aggressive THST. Surprisingly, 
none of the included studies could demonstrate an 
association with AF and lower TSH values, either because 
of the sample size (Abonowara et al. 2012), study design 
and number of events (Wang  et  al. 2015) or different 
TSH assays (Klein Hesselink et al. 2015). Another possible 
explanation is that many of these studies only analyse 
a single TSH measurement at single specific point-time 
during the patient follow-up, which is an inadequate 
measure of ongoing thyroid hormone status. Similarly, 
the single observation that total cumulative radioiodine 
dose might be an independent risk factor for AF has not 
been replicated.
Despite the observation that all the studies including 
controls reported a consistent increase in AF risk in patients 
with DTC relative to healthy counterparts, a notable 
variation in the reported IRs was observed, ranging from 
2.2 to 7.08 in the DTC cohorts. This may be attributed to 
high heterogeneity (between-study variation) regarding 
baseline characteristics of the included population, 
sample size, follow-up time, definition and diagnosis of 
AF (paroxysmal, persistent, permanent, atrial flutter– 
ICD codes or 24 h Holter) and the aggressiveness of TSH 
suppression. More specifically, the lowest incidence rate 
was observed in a DTC cohort from Korea, which is in 
line with epidemiologic data regarding the global burden 
of AF (Chugh et al. 2014). Regional heterogeneity in the 
epidemiology of AF has been observed and reported in the 
literature and specifically, in Asia, lower AF incidence rates 
have been reported either because of sociodemographic 
factors or other factors (Chugh et al. 2014). 
In addition, AF is associated with an increased 
risk of thromboembolic disease and therefore an 
increased incidence of ischemic cerebrovascular disease 
(Chugh et al. 2014). Since DTC patients are more likely 
to be diagnosed with AF, it is plausible to assume that 
there is a similar tendency in incident stroke. However, 
the reports from two studies are conflicting. Toulis et al. 
(2019), found that DTC cohort had a modest risk 
increase for stroke or transient ischaemic attack, while 
Suh et al. (2019) found that a small number of ischaemic 
stroke events in the DTC patients were related to AF, 
although they were at a 2.5-fold risk for other incident 
cerebrovascular disease. 
Table 3 Detailed Newcastle–Ottawa score (NOS) grading for each study.
Author,year Selection Comparability Outcome Total
Abonowara et al. 2012 2 1 3 6
Klein Hesselink et al. 2015 4 2 3 9
Pajamaki et al. 2018 4 2 3 9
Suh et al. 2019 3 2 3 8
Toulis et al. 2019 4 2 3 9
Wang et al. 2015 3 1 3 7
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From a clinical point of view, besides stroke 
prevention (prophylactic use of anticoagulants) a 
discrete approach might warrant further consideration 
in patients with iatrogenic hyperthyroidism regarding 
rhythm and rate control. Although there is no 
definite evidence that beta-blockers can prevent 
AF in subclinical hyperthyroidism, they may offer 
a reasonable option as a rate control intervention 
independently of the underlying disease, especially in 
patients with accompanying hypertension and heart 
failure, conditions that minimize Ic antiarrhythmics 
administration. On the other hand, amiodarone, an 
iodine-rich drug with a half-life of 100 days, is not 
recommended in those patients with DTC for whom RAI 
therapy is indicated since amiodarone interferes with 
131 Iodine uptake for a long time after discontinuation 
and thus, RAI therapy or imaging is postponed if the 
patient has been treated with amiodarone within the 
previous year (Perros et al. 2014).
Strengths and limitations
To the best of our knowledge, this is the first attempt 
to provide an evidence-based estimate regarding the 
long-term effects of DTC treatment on the risk of AF. 
The strengths of our study include the comprehensive 
systematic search and the strict methodology regarding the 
identification of relevant studies and the selection process. 
Studies with unclear methodology or short follow-up time 
were excluded. On the other hand, we acknowledge that 
our meta-analysis had several limitations, including the 
observational and retrospective nature of the included 
studies, the high heterogeneity in study populations and 
baseline characteristics, the lack of data on the RAI cohort, 
thyroid function tests and discrepancies in AF definition 
and TSH assays. Such heterogeneity in population 
characteristics should be interpreted with caution in the 
context of generalizing the results of the present study to 
other settings. The results of our meta-analysis were largely 
attributable to the study conducted in Korea (Suh  et  al. 
2019), which included over 350,000 participants. However, 
even with the exclusion of this study from the sensitivity 
analysis, the incidence of AF in patients with DTC stills 
remains significantly higher compared to controls. 
Moreover, lack of data regarding the histopathological 
type or disease stage and most importantly, the degree and 
aggressiveness of TSH suppression prevented any attempt 
to explore an association either of TSH suppression or 
cumulative RAI dose and development of AF and ischaemic 
cerebrovascular disease. Finally, since several AF cases are 
asymptomatic and, in some studies, the data were derived 
from primary care or claim databases, in which a diagnosis 
is matched to an ICD-10 code, the possibility that 
the true overall incidence rate might be underestimated 
cannot be precluded. 
Conclusion
This is the first meta-analysis to confirm that patients 
with DTC are at a high risk for developing AF, which may 
be attributed to a state of iatrogenic hyperthyroidism due 
Figure 2
Forest plot of aggregate IR of AF in patients with 
DTC.
Figure 3
Forest plot of pooled IRR of AF in patients with 
DTC and their healthy, cancer-free controls 
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to thyrotropin suppression therapy. Hence, periodical 
screening for AF and its complications in selected cases 
might be considered. 
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